Literature DB >> 30742861

Delayed creatine supplementation counteracts reduction of GABAergic function and protects against seizures susceptibility after traumatic brain injury in rats.

Rogerio R Gerbatin1, Luiz Fernando Almeida Silva1, Maurício S Hoffmann2, Iuri D Della-Pace1, Patricia Severo do Nascimento3, Aline Kegler4, Viviane Nogueira de Zorzi4, Jane Marçal Cunha5, Priscilla Botelho5, João Bento Torres Neto5, Ana Flavia Furian3, Mauro Schneider Oliveira3, Michele R Fighera6, Luiz Fernando Freire Royes7.   

Abstract

Traumatic brain injury (TBI) is a devastating disease frequently followed by behavioral disabilities including post-traumatic epilepsy (PTE). Although reasonable progress in understanding its pathophysiology has been made, treatment of PTE is still limited. Several studies have shown the neuroprotective effect of creatine in different models of brain pathology, but its effects on PTE is not elucidated. Thus, we decided to investigate the impact of delayed and chronic creatine supplementation on susceptibility to epileptic seizures evoked by pentylenetetrazol (PTZ) after TBI. Our experimental data revealed that 4 weeks of creatine supplementation (300 mg/kg, p.o.) initiated 1 week after fluid percussion injury (FPI) notably increased the latency to first myoclonic and tonic-clonic seizures, decreased the time spent in tonic-clonic seizure, seizure intensity, epileptiform discharges and spindle oscillations induced by a sub-convulsant dose of PTZ (35 mg/kg, i.p.). Interestingly, this protective effect persists for 1 week even when creatine supplementation is discontinued. The anticonvulsant effect of creatine was associated with its ability to reduce cell loss including the number of parvalbumin positive (PARV+) cells in CA3 region of the hippocampus. Furthermore, creatine supplementation also protected against the reduction of GAD67 levels, GAD activity and specific [3H]flunitrazepam binding in the hippocampus. These findings showed that chronic creatine supplementation may play a neuroprotective role on brain excitability by controlling the GABAergic function after TBI, providing a possible new strategy for the treatment of PTE.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Creatine; Epilepsy; Epileptiform discharge; Fluid percussion injury; GABA; Seizure

Mesh:

Substances:

Year:  2019        PMID: 30742861     DOI: 10.1016/j.pnpbp.2019.02.004

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  6 in total

Review 1.  Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular Mechanisms, Biomarkers, and Novel Therapeutic Interventions.

Authors:  Victoria M Golub; Doodipala Samba Reddy
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

Review 2.  Novel Approaches to Prevent Epileptogenesis After Traumatic Brain Injury.

Authors:  Chris G Dulla; Asla Pitkänen
Journal:  Neurotherapeutics       Date:  2021-09-30       Impact factor: 6.088

3.  Seizure Susceptibility and Sleep Disturbance as Biomarkers of Epileptogenesis after Experimental TBI.

Authors:  Pedro Andrade; Leonardo Lara-Valderrábano; Eppu Manninen; Robert Ciszek; Jesse Tapiala; Xavier Ekolle Ndode-Ekane; Asla Pitkänen
Journal:  Biomedicines       Date:  2022-05-14

4.  Maternal Creatine Supplementation Positively Affects Male Rat Hippocampal Synaptic Plasticity in Adult Offspring.

Authors:  Stefano Sartini; Davide Lattanzi; Michael Di Palma; David Savelli; Silvia Eusebi; Piero Sestili; Riccardo Cuppini; Patrizia Ambrogini
Journal:  Nutrients       Date:  2019-08-27       Impact factor: 5.717

5.  The Complexity of Secondary Cascade Consequent to Traumatic Brain Injury: Pathobiology and Potential Treatments.

Authors:  Nidhi Khatri; Bommaraju Sumadhura; Sandeep Kumar; Ravinder Kumar Kaundal; Sunil Sharma; Ashok Kumar Datusalia
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

Review 6.  Novel Synthetic and Natural Therapies for Traumatic Brain Injury.

Authors:  Denise Battaglini; Dorota Siwicka-Gieroba; Patricia Rm Rocco; Fernanda Ferreira Cruz; Pedro Leme Silva; Wojciech Dabrowski; Iole Brunetti; Nicolò Patroniti; Paolo Pelosi; Chiara Robba
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.